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Innate sensors play a critical role in the early innate immune responses to invading
pathogens through sensing of diverse biochemical signatures also known as pathogen
associated molecular patterns (PAMPs). These biochemical signatures primarily consist of
a major family of biomolecules such as proteins, lipids, nitrogen bases, and sugar and its
complexes, which are distinct from host molecules and exclusively expressed in pathogens
and essential to their survival.The family of sensors known as pattern recognition receptors
(PRRs) are germ-line encoded, evolutionarily conserved molecules, and consist of Toll-like
receptors (TLRs), RIG-I-like receptors (RLRs), NOD-like receptors (NLRs), C-type lectin-
like receptors (CLRs), and DNA sensors. Sensing of PAMP by PRR initiates the cascade of
signaling leading to the activation of transcription factors, such as NF-κB and interferon reg-
ulatory factors (IRFs), resulting in a variety of cellular responses, including the production
of interferons (IFNs) and pro-inflammatory cytokines. In this review, we discuss sensing of
different types of glycosylated PAMPs such as β-glucan (a polymeric sugar) or lipopolysac-
charides, nucleic acid, and so on (sugar complex PAMPs) by different families of sensors,
its role in pathogenesis, and its application in development of potential vaccine and vaccine
adjuvants.
Keywords: innate immunity, innate sensors, sugar associated PAMPs, disease pathogenesis, vaccinology
INTRODUCTION
The complexity of carbohydrates exhibits enormous diversity
in structure and function in the living system. Carbohydrates
play crucial role in fundamental biological processes such as
energy requirements and modification of basic macromolecules
Abbreviations: Abs, antibodies; AG, arabinogalactan; AIM2, absent in melanoma2;
APCs, antigen presenting cells; ASC, apoptosis-associated speck-like protein con-
taining a CARD; Bcl-10, B cell lymphoma-10; bFGF, basic fibroblast growth fac-
tor; BIR, baculoviral inhibitor of apoptosis repeats; CARD, caspase activation
and recruitment domain; cGAMP, cyclic guanosine monophosphate-adenosine
monophosphate; cGAS, cyclic-GMP-AMP synthase; CLRs, c-type lectin receptors;
CRD, carbohydrate recognition domain; CSP, circumsporozoite protein; CTD, c-
terminal domain; CTL, cytotoxic T lymphocytes; DAI, DNA-dependent activator
of IFN-regulatory factors; DC-SIGN, DCs specific intracellular adhesion molecule
(ICAM)-3 grabbing non-integrin; DDA, dimethyl dioctadecyl ammonium; Dectin,
DCs associate C-type lectin; ECD, extra cellular domain; FADD, fas associated pro-
tein with death domain; FcRγ, Fc receptor γ-chain; FIA, Freund’s incomplete adju-
vant; GLA, glucopyranosyl lipid; GM-CSF, granulocyte macrophage colony stim-
ulating factor; GNR, gold nano rods; GPI, glycophosphatidylinositol; HA, hemag-
glutinin; HBsAg, hepatitis B virus (HBV) surface antigen; HCV, hepatitis C virus;
HEV, hepatitis E virus; HIV, human immunodeficiency virus; HLA, human leuko-
cyte antigen; HSV, herpes simplex virus; iE-DAP, d-gamma-Glu-meso-DAP dipep-
tide; IFI16, IFN-γ-inducible protein-16; IRAKs, interleukin-1 receptor-associated
kinases; IRFs, interferon (IFN) regulatory factors; ISGs, IFN stimulatory genes; ISRE,
IFN stimulatory response elements; ITAMs; immunoreceptor tyrosine-based acti-
vation motifs; JNKs, c-Jun N-terminal kinases; LAM, lipoarabinomannan; LGP2,
laboratory of genetics and physiology 2; LPS, lipopolysaccharide; LRRFIPI, leucine
rich repeat (LRR) Fli-I interacting protein; L-SIGN, liver/lymph-node specific
ICAM-3grabbing non-integrin; LTA, lipoteichoic acid; MALT-1, mucosa-associated
like proteins and lipids to make them functional macromolecules
for cellular functions such as cellular communication, cell-type
specificity, cell signaling, and so on. The diversification of car-
bohydrate structure is because of branching and complexing of
monomers or polymers or through formation of glycoconjugates
lymphoid tissue lymphoma gene-1; MAPKs, mitogen-activated protein kinases;
MCL, macrophage C-type lectin; MDA5, melanoma-differentiation-associated gene
5; MD-2, myeloid differential factor 2; MDP, MurNAc-l-Ala-d-isoGln; MRE 11,
meiotic recombination 11 homolog A; MTB, Mycobacterium tuberculosis; MyD88,
myeloid differentiation primary response gene 88; NF-κB, nuclear factor kappa
B; NLRPs, NLR family pyrin domain containing proteins; NLRs, nucleotide
oligomerization domain (NOD) like receptors; ODNs, oligodeoxynucleotides;
OAS1, oligoadenylate synthase 1; OVN, ovalbumin antigen; PAMPs, pathogen asso-
ciated molecular patterns; PBMCs, peripheral blood mononuclear cells; pDCs,
plasmacytoid dendritic cells (DCs); PD, programed death; PGN, peptidoglycan; PG-
TA, peptidoglycan teichoic acid; PLC, paclitaxol lipopolysaccharide complex; PRRs,
pattern recognition receptors; PS, phosphorothioated; PYD, pyrin domain; RAD50,
DNA repair protein 50; RAGE, receptors for advanced glycation; RD, repressor
domain; RIP2, receptor-interacting serine/threonine-protein kinase 2; RSV, respi-
ratory syncytial virus; SAV, salmonid alpha virus; SCPs, sugar complex PAMPs;
SLE, systemic lupus erythematosus; STING, stimulator of IFN genes; Syk, spleen
tyrosine kinase; SIII, type III pneumococcal polysaccharide; TA, teichoic acid; TAK-
1, transforming growth factor activated kinase-1; TBK1, TANK-binding kinase-1;
TDB, trehalose-6, 6-dibehenate; TDM, trehalose dimycolate; TIRAP, TIR-containing
adaptor protein; TIR, toll/interleukin receptor; TLRs, toll-like receptors; TNF, tumor
necrosis factor; TRADD, tumor necrosis factor receptor type-1associated death
domain protein; TRAF6, TNF receptor-associated factor 6; TRAM, TRIF-related
adaptor molecule; TRIF, TIR domain containing adaptor-inducing IFN-β; TRIM,
tripartite motif-containing protein; WIV, whole inactivated virus.
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such as glycoproteins and glycolipids. These glycoconjugates are
fundamental components of both the host and pathogens and play
an important role in host–pathogen interactions and provide the
molecular basis for discrimination and elicitation of appropriate
immune responses in the host (1–3). Pathogen associated mol-
ecular patterns (PAMPs) are molecular signature of pathogens
recognized by the host germ-line encoded pattern recognition
receptors (PRRs), which are classified as toll-like receptors (TLRs),
retinoic acid-inducible gene (RIG)-I-like receptors (RLRs), C-type
lectin receptors (CLRs), and nucleotide oligomerization domain
(NOD)-like receptors (NLRs), and DNA sensors (4–8). Most of
the PAMPs such lipopolysaccharides (LPS) from gram-negative
bacteria, bacterial/viral nucleic acid including single-stranded
RNA (ssRNA), double-stranded RNA (dsRNA), CpG rich DNA,
β-glucans from fungus, and trehalose dimycolate (TDM) from
Mycobacterium contain sugar as integral part of structure. PAMPs,
which either constituted of sugar or contain sugar as a component
of the complex structure can be given a new terminology as sugar
complexed PAMPs (SCPs). The SCPs group of PAMPs is a largest
group of PAMPs and almost all the PAMPs are grouped into it
except pure lipid and protein such as flagellin. SCPs constitute
essential structural and functional moieties of the pathogen that
are essential for infection and establishment of disease in the host.
On other hand these SCPs also play an important role in vaccine
biology. The sensing of SCPs in various compartments of cells by
different PRRs activates an array of biochemical reactions, leading
to the activation of transcription factors such as nuclear factor
kappa B (NF-κB) and interferon (IFN) regulatory factors (IRFs)
for induction of inflammatory cytokine and type-I IFNs respec-
tively. Additionally, these innate immune responses also play a
pivotal role in initiation of pathogen-specific adaptive immunity
via T and B lymphocytes. In this review, we will discuss different
kinds of SCPs, their recognition by PRRs, and role in disease, and
how these PAMPs can be explored for therapeutic application as
vaccines and/or vaccine adjuvants.
SENSING OF SCPs BY PRRs
Large numbers of SCPs from different classes of pathogens (bac-
teria, virus, and fungi) are reported and sensing of these PAMPs
by different families of PRRs is described below in detail.
SENSING OF SCPs BY TLRs
Toll-like receptors sense various kinds of SCPs such as LPS, ssRNA,
and hypomethylated dsDNA (CpG) in different cellular compart-
ments of the cells. The sensing of SCPs by TLRs is described in
several review and listed in Tables 1 and 2 (7, 9–11). The recently
discovered TLR13 is involved in sensing of bacterial 23S rRNA
(12). TLR1, TLR2, TLR4, and TLR6 are plasma membrane local-
ized TLRs, mainly sense hydrophobic SCPs (Table 1) such as
LPS, while TLR3, TLR7, TLR8, and TLR9 are endosome localized
TLRs, sense hydrophilic SCPs (Table 2) such as 5′-ppp-ssRNA
(9, 13). TLRs are comprised of N-terminal ligand binding extra
cellular domain (ECD) with 19–25 leucine rich repeat (LRRs)
motifs, single transmembrane domain, and C-terminal intracel-
lular toll/interleukin receptor (TIR) domain (14, 15). LRRs are
consists of “xLxxLxLxx”where“L”stands for leucine and“x”stands
for any amino acid, and it is important for recognition of PAMPs.
Binding of PAMPs to LRRs leads to receptor dimerization that
induces conformational changes to TIR domain for recruitment
of an adaptor and activation of the signaling cascade (13, 15).
Sensing of PAMPs by TLR2 induces oligomerization with TLR1
or TLR6, while TLR3, TLR7, TLR8, and TLR9 form homodimers;
however, the sensing mechanism for TLR13 is not well known. It
is possible that TLR13 forms a homodimer for the activation of a
downstream signaling pathway. The glycolipid LPS, which is struc-
turally constituted of lipid A,central oligosaccharide,and antigenic
O-polysaccharide (16) is sensed by TLR4 (17, 18) (Table 1) along
with co-receptors known as myeloid differential factor 2 (MD-2)
and cluster CD14 (17, 19, 20). TLR2 senses a large class of bacterial
SCPs such as lipoteichoic acid (LTA) (21–23), teichoic acid (TA)
(21), TDM (24), peptidoglycan (PGN) (21), glycophosphatidyli-
nositol (GPI) anchored proteins (25), lipoarabinomannan (LAM)
(26), and arabinogalactan (AG) (27, 28). Nucleic acids, the pentose
sugar containing PAMPs are sensed by endosomal TLRs. The bac-
terial and viral DNA, which are hypomethylated compared to the
host DNA, sensed by TLR9 (29–31). The viral dsRNA and ssRNA
are sensed by TLR3 and TLR7, respectively (32–34). Recently,
human TLR8 was shown to sense viral ssRNA-derived from human
immunodeficiency virus (HIV) (35, 36).
SENSING OF SCPs BY RLRs
Retinoic acid-inducible gene-I-like receptors, retinoic acid-
inducible gene I (RIG-I), melanoma-differentiation-associated
gene 5 (MDA5), and laboratory of genetics and physiology 2
(LGP2) (37), sense RNA SCPs (Table 2). Studies on RIG-I and
MDA5 knockout mice demonstrate that RIG-I and MDA5 sense
viral RNA from different classes of RNA viruses (38,39) and induce
antiviral immune response; however, LGP2 functions as a regula-
tory molecule for RIG-I and MDA5 mediated sensing of viral RNA
(40, 41). RIG-I and MDA5 are comprised of two N-terminal cas-
pase activation and recruitment domains (CARD), middle ATPase
containing DExD helicase domain (DExD helicase), and a C-
terminal domain (CTD). The N-terminal CARD of RIG-I and
MDA5 is necessary for recruitment of adaptor and downstream
signaling. RIG-I mainly senses small size (<1 kb) RNA contain-
ing 5′ppp-ssRNA moieties (42), which could be ssRNA (43, 44)
or dsRNA (45), while MDA5 mainly recognizes larger size RNA
(>1 kb) from various kinds of viruses and discussed in reviews
(46). MDA5 recognizes internal duplex structure of RNA, while
RIG-I recognizes the terminus of RNA (47).
SENSING OF SCPs BY NLRs
NOD-like receptors are cytosolic PRR consisting of 22 and 24
receptors, in humans and mice, respectively (48) and categorized
into four subfamilies, NLR-A, NLR-B, NLR-C, and NLR-P, where
A, B, C, and P represent acidic trans-activating domain (AD), bac-
uloviral inhibitor of apoptosis repeats (BIR), CARD, and pyrin
domain (PYD) respectively. Although these NLRs sense various
kinds of PAMPs (7), only SCP-sensing NLRs are in the scope of
this review. Nucleotide oligomerization domain (NOD) 1 and 2,
belongs to NLR-C family, sense PGN (Table 2) from bacteria (49–
51), are comprised of C-terminal LRRs, central oligomerization
domain, and N-terminal CARD. NOD1 senses d-gamma-Glu-
meso-DAP dipeptide (iE-DAP) (49, 52); however, NOD2 senses
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Table 1 | Sensing of SCPs by plasma membrane localized PRRs.
SCPs Sensors Signaling axis Immune effector response Reference
α-Mannans Dectin-2 FcRγ-Syk-PLCγ-(CARD9-NF-κB/
MAPK/Calcineurin-NFAT)
Inflammatory cytokines Saijo et al. (73)
β-Glucans Dectin-1 Syk-PLCγ-(CARD9-NF-κB/
MAPK/Calcineurin-NFAT)
Inflammatory cytokines Taylor et al. (72)
Glycoprotein DC-SIGN, L-SIGN,
Dectin-2
Ras/Pak/Src-Raf-NF-κB Inflammatory cytokines Ishikawa et al. (77), Ludwig
et al. (80), Zhao et al. (82),
Svajger et al. (83)
FcRγ-Syk-PLCγ-(CARD9-NF-κB/
MAPK/Calcineurin-NFAT)
Glycolipid Mincle FcRγ-Syk-PLCγ-(CARD9-NF-κB/
MAPK/Calcineurin-NFAT)
Inflammatory cytokines Ishikawa et al. (77)
Trehalose dimycolate
(TDM)
Mincle, MCL, TLR2 FcRγ-Syk-PLCγ-(CARD9-NF-κB/
MAPK/Calcineurin-NFAT)
Inflammatory cytokines Bowdish et al. (24), Wells
et al. (74), Miyake et al. (76)
TRAP-MyD88-TRAFs-IKKα/β-NF-κB
Teichoic acid (TA) TLR2 TIRAP-MyD88-TRAFs-IKKα/β-NF-κB Inflammatory cytokines Schwandner et al. (21)
Arabinogalactan TLR2 TIRAP-MyD88-TRAFs-IKKα/β-NF-κB Inflammatory cytokines and
type-I IFNs
Strohmeier et al. (27),
Underhill et al. (28)TIRAP-MyD88-TRAFs-TBK-IRFs
Lipopolysaccharide
(LPS)
TLR4, TLR2, DC-SIGN MyD88/TRIF/TIRAP/TRAM-
IKKα/β/IKKi-NF-κB/IRFs
Inflammatory cytokines and
type-I IFNs
Hoshino et al. (18), Zhang
et al. (78), Takeuchi et al. (194)
TIRAP/MyD88-TRAFs-IKKα/β-NF-κB
Ras/Pak/Src-Raf-NF-κB
Lipoarabinomannan
(LAM)
TLR2/TLR1 TIRAP-MyD88-IKKi-IRFs Inflammatory cytokines and
type-I IFNs
Means et al. (26)
Peptidoglycan (PGN) TLR2 TIRAP-MyD88-TRAFs-IKKα/β-NF-κB Inflammatory cytokines Schwandner et al. (21)
GPI anchored protein TLR1/TLR2 TIRAP-MyD88-TRAFs-IKKα/β-NF-κB Inflammatory cytokines Campos et al. (25)
Table 2 | Sensing of SCPs by cytosolic PRRs.
SCPs Sensors Signaling axis Immune effector response Reference
Peptidoglycan NOD1, NOD2 RIP2-NF-κB or RIP2-
CARD9-MAPK-AP1
Inflammatory cytokines Girardin et al. (49), McDonald et al. (50),
Chamaillard et al. (52)
β-Glucans NLRP3 ASC-Caspase-1-IL-1β Inflammatory cytokines Kankkunen et al. (58)
Peptidoglycan NLRP1 ASC-Caspase-1-IL-1β Inflammatory cytokines Faustin et al. (55)
CpG-DNA TLR9, DHX9, DHX36 MyD88-IKKi-IRFs Type-I IFNs Hemmi et al. (29), Peter et al. (31),
Zhang et al. (126)IPS-1-TBK-IKKi-IRFs
5′ppp-ssRNA RIG-I, MDA5 IPS-1-TBK-IKKi-IRFs Type-I IFNs Hornung et al. (42)
ssRNA TLR7, TLR8 MyD88-IKKα/β-NF-κB Inflammatory cytokines
and type-I IFNs
Hemmi et al. (33), Han et al. (35), Tanji
et al. (36)MyD88-IKKi-IRFs
23SrRNA TLR13 MyD88-IKKα/β-NF-κB Inflammatory cytokines Oldenburg et al. (12)
dsDNA DAI, IFI16, STING, AIM2,
DDX41, MRE11, cGAS
MyD88-IKKi-IRFs Inflammatory cytokines
and type-I IFNs
Rathinam et al. (59), Takaoka et al. (117),
Unterholzner et al.(120), Ishikawa and
Barber (121), Ablasser et al. (123), Zhang
et al.(126), Kondo et al. (128)
IPS-1-TBK/IKKi-IRFs
ASC-Caspase-1-IL-1β
dsRNA TLR3, RIG-I, MDA5 TRIF-TBK-IKKi-IRFs Type-I IFNs Alexopoulou et al. (32), Kato et al. (38),
Kato et al. (39), Kumar et al. (89),
Yoneyama et al. (195)
IPS-1-TBK-IKKi-IRFs
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MurNAc-l-Ala-d-isoGln (MDP) of bacteria (49, 50). NOD1 and
NOD2 receptors sense a large class of bacteria and discussed in
detail in several reviews (7, 9). The PYD is containing NLRP1,
NLRP3, and HIN domain containing cytosolic DNA sensor absent
in melanoma 2 (AIM2) sense various SCPs from bacteria (MDP,
RNA, and DNA), virus (RNA and DNA), and fungi (β-glucan
and mannans) as an oligomeric complex known as inflammasome
(53, 54). Bacterial, viral, and fungal PAMPs can activate different
NLR inflammasome complexes and AIM2 inflammasome com-
plex (54–59). NLRP3 inflammasome is the most studied inflam-
masome senses β 1, 3 d-glucan (Table 2) and regulates innate and
adaptive immunity, particularly B-lymphocytes mediated anti-
bodies (Abs) responses (58). NLRP1 inflammasome senses MDP,
but the exact mechanism is not well understood (55). AIM2 (also
known as PYHIN4) is a member of PYHIN (pyrin and HIN-
200 family) and plays an important role in sensing of microbial
DNA (Table 2) is comprised of N-terminal PYD and C-terminal
HIN domain. The HIN domain sense dsDNA and PYD interacts
with PYD of apoptosis-associated speck-like protein containing
a CARD (ASC). The complex of DNA, AIM2, and ASC acti-
vates inactive caspase-1 and forms an inflammasome complex for
production of interleukin (IL)-1 family cytokines (56, 57, 59).
SENSING OF SCPs BY CLR
C-type lectin-like receptors sense SCPs from various kinds of
pathogens, such as parasites (60), fungi (8, 61), bacteria, and
viruses (62, 63) consist of more than 1000 members (60, 64).
The number of extracellular carbohydrate recognition domain
(CRD) and their cellular localization classifies CLRs to type-I
transmembrane, type-II transmembrane, and soluble CLRs (65);
where type-I CLRs contain multiple CRD and type-II CLRs con-
tains single CRD (66). Furthermore, based on domain organiza-
tion and sequence homology, CLRs are grouped into 17 clusters
(67). Among these clusters DCs associate C-type lectin (Dectin)-1
and 2 clusters are the most widely explored (8, 68, 69). Dectin-
1 senses fungal β-glucan (Table 1) (8, 70–72), which is mediated
through hydrophobic entrapment of β-glucan at a groove between
Trp221 and His223 residue of Dectin-1 (71). Structurally Dectin-1
is comprised of a CRD that connected to transmembrane domain
through a stalk region, which contains a small intracellular tail,
where immunoreceptor tyrosine-based activation motif (ITAM)-
like (YxxL) and tri-acidic (DED) motifs exist. “Y” represents tyro-
sine, “x” can be any amino acid, and “D” and “E” are glutamic acid
and aspartic acid, respectively (8). Dectin-2 senses α-mannans
(Table 1); mice lacking Dectin-2, challenged with α-mannans
derived from Candida albicans do not induce cytokines suggesting
that Dectin-2 plays a pivotal role in sensingα-mannans (73). Struc-
turally, Dectin-2 is comprised of one CTLD domain, and a short
transmembrane domain that is associated with ITAM containing
Fc receptor γ-chain (FcRγ) receptor. Mincle and macrophage C-
type lectin (MCL; also known as Clec4d) receptor (Table 1) sense
TDM (74–76). Similar to Dectin-2, Mincle also contain one CTLD,
a short transmembrane domain, and an attached ITAM containing
FcRγ receptor; however, while MCL is a gene duplication prod-
uct of Mincle and structurally belongs to the same CLR subgroup
(76). Recently, it has been reported that opportunistic skin fun-
gal pathogen Malassezia is sensed by Mincle and Dectin-2, where
Mincle senses glucosyl-glycolipid and mannosyl-glycolipid and
Dectin-2 senses O-linked mannobiose-rich glycoprotein; however,
Mincle and Dectin-2 deficient mice were unresponsive to these
ligands suggesting that Mincle and Dectin-2 sense distinct lig-
ands from fungus Malassezia and induce host immune response
(77). DC-SIGN (also known as CD209) a type-II CLR senses var-
ious kinds of SCPs (Table 1) such as LPS (78), G-glycoprotein
from respiratory syncytial virus (RSV), E1 and E2 glycoproteins
from hepatitis C virus (HCV), and glycoprotein-140 (gp-140)
from HIV (79, 80). Furthermore administration of LPS in mice
promotes differentiation of monocytes to DC-SIGN receptor rich
DCs (81), suggesting that DC-SIGN plays a crucial role in recogni-
tion of microbial pathogens. Liver/lymph-node specific ICAM-3
grabbing non-integrin (L-SIGN; also known as CD209L) senses
E2 glycoprotein from HCV (82). Sensing of glycoproteins by
DC-SIGN and L-SIGN mediates viral attachment and leads to
internalization of the virus into non-lysosomal compartments in
host cells (80, 82, 83). MBL, the soluble CLR, senses microbial
pathogens through their sugar moieties in a non-specific man-
ner and promotes complement fixation, for which MBL forms a
multiprotein complex known as collectins (84).
PRR SIGNALING
After sensing of SCPs, PRRs recruit different adaptors for effector
responses, which are mainly elicited through secretion of innate
cytokines such as type I IFNs and inflammatory cytokines.
TLR SIGNALING
Sensing of SCPs by TLR induces conformational changes and
oligomerization of receptors, which leads to the recruitment of
various adaptor(s) molecules to the TIR domain, which include
myeloid differentiation primary response gene 88 (MyD88),
TIR domain containing adaptor-inducing IFN-β (TRIF), TIR-
containing adaptor protein (TIRAP), and TRIF-related adaptor
molecule (TRAM). The signaling pathways activated by different
TLRs are MyD88-dependent and MyD88-independent (Figure 1)
and described in several reviews in detail (7, 10, 11, 85). TLR signal-
ing is regulated at three different levels, which include recruitment
of adaptors, stability of signaling intermediates, and transcription
regulation (86). A recent study shows that vitamin-D also plays a
crucial role in regulation of TLR signaling (87).
RLR SIGNALING
Ligation of RNA to RIG-I and MDA5 promotes receptor oligomer-
ization and recruitment of an adaptor IPS-1/MAVS/VISA/Cardiff
(47, 88–90). Encounter of viral RNA with these sensors leads to the
activation of sensors though accessibility of CARD for recruitment
of CARD containing IPS-1 through K63 linked ubiquitination.
The downstream signaling and its regulation are discussed in sev-
eral reviews (37, 91–94). Recently, in vitro studies show that recog-
nition of RNA by MDA5 requires CTD domains and forms head to
tail oligomer strand around the RNA, leaving two CARD exposed
outside, which oligomerize and recruit IPS-1, forming a string-like
structure around the oligomerized MDA5 assembly (47). IPS-1
activates IKK-related kinase TBK1 and IKKi/IKKε, which acti-
vates transcription factor IRFs (mainly IRF1, IRF3, and IRF7), and
subsequent transcription of type-I IFNs (Figure 2). It has been
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FIGURE 1 | Sensing of SCPs through membrane associated PRRs,TLRs,
and CLRs. In macrophages and dendritic cells plasma membrane localized
TLRs (TLR1, TLR2, TLR4, and TLR6) and endosomal localized TLRs (TLR3,
TLR7, TLR8, and TLR9) and TLR13 sense various SCPs as homo or
heterodimer (shown inTable 1). TLR recruits MyD88, TRIFs, TIRAP, and TRAM
adaptors for induction of inflammatory cytokines and type-I IFNs through
activation of NF-κB and IRFs (IRF3 and IRF7) via IKKα/β and TBK1/IKK1,
respectively. Dectin-1, Dectin-2, Mincle, and MCL are representative CLRs of
Dectin-1 and Dectin-2 clusters. Sensing of various SCPs by Dectin-1 and
Dectin-2 (shown inTable 1) recruits, Syk adaptor which further recruits PLCγ
and activate cascade of signaling for induction of inflammatory cytokines via
NF-κB and MAP kinases.
shown that IPS-1 is localized in mitochondria and peroxisomes
and signals through IRF3 and IRF1, respectively (95). Further-
more, IPS-1 also induces production of inflammatory cytokines
and requires tumor necrosis factor receptor type-1 associated
death domain protein (TRADD), Fas associated protein with death
domain (FADD), caspase-8, and caspase-10 (96, 97). RLR signal-
ing is tightly regulated at multiple levels that include regulation
of RNA sensing by LGP2 (40, 41), post-translational modification
(PTM) of IPS-1, RIG-I, and MDA5 (98, 99), disruption of RLRs
(RIG-I/MDA5)-IPS-1 signaling axis (100), destabilization of IPS-
1, modulation of mitochondrial dynamics, and IPS-1 activation
and regulation of downstream signaling molecules (99).
NLR SIGNALING
Ligand binding leads to self-oligomerization of NOD1 and NOD2
and recruits an adaptor Receptor-interacting serine/threonine-
protein kinase 2 (RIP2). RIP2 is a serine threonine kinase and
activates transforming growth factor activated kinase-1 (TAK-1)
that subsequently activates NF-κB and mitogen-activated protein
kinases (MAPKs) such as p38 and c-Jun N-terminal kinases (JNKs)
(Figure 2). MAPKs is activated through an adaptor CARD9 (7,
101–104). NLR such as NLRP1 and NLRP3 induce IL-1 fam-
ily cytokines, where ASC functions as a signaling adaptor and
induces caspase-1-dependent maturation of IL-1 family cytokines
and plays a crucial role in inflammatory responses and pyroptosis
(103, 105, 106). Among all known inflammasome, NLRP3 is the
most investigated inflammasome and it can be activated by mul-
tiple factors such as components of pathogenic microbes, tissue
damage, autophagy, type-I IFNs, T cells, metabolic dysregulation,
miRNA, and so on (107–110). Furthermore, viruses also enhance
the negative regulatory mechanism of hosts to promote survival
within the host (111). Activation of NLRP1 induces pyroptosis
in hematopoietic cells and inhibition of NLRP1 may play a pro-
tective role in individuals having blood disorders such as anemia
and leukopenia and suffering from bacterial septic shock (112).
Distinct from NLRP1 and NLRP3, inflammasome AIM2 activates
caspase-1 and NF-κB in an ASC dependent manner (56).
CLR SIGNALING
Sensing of SCPs by CLRs activates multiple signaling cascades
through their own ITAMs or interacting with ITAM-motif con-
taining adaptor proteins such as FcRγ. Signaling cascades lead to
activation of NF-κB through a spleen tyrosine kinase (Syk) and
CARD9 dependent pathway(s). Binding of ligands to Dectin-1
promotes phosphorylation of YxxL motifs through Syk that pro-
motes recruitment of adaptor CARD9, which exists as a complex
B cell lymphoma-10 (Bcl-10) and mucosa-associated lymphoid
tissue lymphoma gene-1 (MALT-1), and subsequently activates
IKK kinase complex (Figure 2). The activated IKK complex acti-
vates canonical NF-κB subunits p65 and c-Rel to induce produc-
tion of multiple cytokines such as IL-6, IL-10, IL-23, IL-1β, and
TNF-α through a subset of T cells such as Th1, Th2, Th17, and
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FIGURE 2 | Sensing of SCPs through cytosolic PRRs, RLRs, NLRs, and
cytosolic DNA sensors. RLRs family member, RIG-I and MDA5 sense viral
dsRNA (shown inTable 2), recruits an adaptor IPS-1 for induction of type-I
IFNs and inflammatory cytokines. STING, a molecule plays a pivotal role in
sensing of RNA. Several DNA sensors induce inflammatory cytokine and
type-I IFNs in STING dependent and independent manner. NLRs family
member, NOD1, NOD2, and inflammasome (mainly NLRP1 and NLRP3 and
AIM2) induces inflammatory cytokine. NOD1 and NOD2 sense various SCPs
(shown inTable 2) recruit an adaptor RIP2 and CARD9 for induction of
inflammatory cytokines. Activation of inflammasome complex after
stimulation with appropriate SCPs (shown inTable 2) process an inactive,
proIL-1 family cytokine to active IL-1 family cytokine.
THF (113–115). In DCs, assembling of CARD9/Bcl-10/MALT-1
complex is dependent on paclitaxel-lipopolysaccharide complex
(PLC)-γ2 receptor (8, 116). Alternatively, non-canonical activa-
tion of NF-κB takes place through Ras-RAF1 mediated phospho-
rylation of p65 at serine 279. Binding of activated p65 with histone
acetyl transferase CBP/p300 promotes cytokines synthesis; how-
ever, its binding with b-Rel inhibits the NF-κB activity (66, 113,
115). For downstream signaling,Dectin-2 and Mincle interact with
signaling adaptor FcRγ through positively charged amino acids
that promote phosphorylation of ITAMs of FcRγ and subsequent
recruitment of Syk. Furthermore, Dectin-2 activates NF-κB (p65–
p50) and Mincle activates NF-κB in a CARD9 dependent manner
(Figure 2) (115).
SCPs AND CYTOSOLIC DNA SENSORS
DNA-dependent activator of IFN-regulatory factors (DAI) is the
first identified cytosolic DNA sensor that recognizes dsDNA and
induces production of type-I IFNs (117); however, DAI-knockout
cells display normal responses to poly(dA:dT), a synthetic analog
of B-DNA, suggesting the existence of multiple sensors for cytoso-
lic dsDNA (118). Nucleic acid binding protein known as leucine
rich repeat Fli-I interacting protein (LRRFIPI) is a cytosolic sensor
of AT rich B-DNA and GC rich Z-DNA and induces production of
IFN-β, and the sensing is dependent on β-Catenin (119). Absent
in melanoma 2 (AIM2), a member of the hematopoietic IFN-
inducible nuclear protein HIN-200 family, has been recognized
as a cytosolic DNA sensor (57) and plays a crucial role against
cytosolic bacteria and DNA viruses (59). IFN-γ-inducible protein-
16 (IFI16; also known as p204) induces type-I IFNs in stimulator
of IFN genes (STING) dependent manner (120). STING is an
endoplasmic reticulum (ER) localized dsDNA sensor and induces
activation of transcription factor NF-κB and IRF3 for down-
stream signaling (Figure 2) (121). Sensing of dsDNA by STING
is positively regulated by IFN-inducible TRIM-56, which leads to
production of IFN-β (122). Recently, a nucleotidyltransferase fam-
ily member known as cyclic guanosine monophosphate-adenosine
monophosphate (cyclic-GMP-AMP, or cGAMP) synthase was
identified as a cytosolic DNA sensor that senses DNA in a STING
dependent manner. During this process cGAMP synthase (cGAS)
binds to microbial DNA and synthesizes secondary messenger
cGAMP that interacts with STING and activates IRF3, which
subsequently leads to transcription of type-I IFNs. The crystal
structure of cGAS alone and bound with DNA, ATP, and GTP
demonstrates that cGAS is structurally similar to dsRNA sensor 2′–
5′ oligoadenylate synthase (OAS1), but it contains a unique zinc-
thumb structure through which it recognizes microbial B-DNA
(123–125). DEAH (Asp-Glu-Ala-His) box containing polypeptide
9 and 36 (also known as DHX9 and DHX36) senses hypomethy-
lated CpG DNA in Myd88 dependent manner; however, DDX41, a
newly identified PRR, senses dsDNA in STING dependent manner
and induces IFN-β (126). DDX41 is negatively regulated through
E3 ubiquitin ligase TRIM21, where TRIM21 ubiquitinates DDX41
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at K9, K48, and K115 positions, which leads to its degradation
(127). Meiotic recombination 11 homolog A (MRE11) in asso-
ciation with DNA repair protein 50 (RAD50) recognizes various
kinds of dsDNA in cytosol and induces production of type-I IFNs
in a STING-IRF3 dependent manner (128). Although stimulation
of granulocyte-monocyte-colony stimulating factor (GM-CSF)
induces bone marrow-derived DCs (GM-DCs) with herpes sim-
plex virus (HSV-1) and Listeria monocytogenes enhances type-I
IFNs, siRNA mediated silencing of MRE11 does not abrogate the
response, suggesting that further studies are required to under-
stand the role of MRE11 in innate immunity (128). It can be
concluded that sensing of DNA and RNA SCPs by cytosolic PRRs
is more complicated than thought. Although several sensors have
been discovered, the general consensus is that there may be some
more cytosolic nucleic acid sensors that sense the respective DNA.
SCPs MEDIATED IMMUNE DYSREGULATION/DISEASE
Sensing of PAMPs by PRRs initiates innate immune responses
through secretion of inflammatory cytokines, and subsequent
B and T lymphocyte mediated humoral and cellular immune
responses are essential for eradication of invading pathogens.
However, excessive or hyper activation of innate and adaptive
immune responses could be detrimental to the host (129, 130).
SCPs are known to induce lethal immune response in the host,
such as septic shock, which is characterized by a storm of inflam-
matory cytokines in the host after infection with gram bacteria.
The LPS (also known as endotoxin) induces activation of myeloid
and non-myeloid lineage of cells (131) and leads to cytokine
mediated immune shock that is generally known as septic shock;
the mechanism of LPS mediated immune stimulation is largely
studied in laboratory animals, which is a reflective process for
humans. Administration of LPS in mice induces inflammatory
lesions through excessive secretion of TNF-α, IL-1β from mono-
cytes, and macrophages that ultimately culminates in septic shock
mediated death (132). LPS induces lethal effects due to TLR4-
CD14-MD12 receptor complex mediated recruitment of multiple
signaling adaptors (MyD88, TRAF6, TRAM, and TRIF). Septic
shock is associated with progression of kidney disease with inci-
dent microalbuminuria and induces degeneration of neurons in
individuals with type-I diabetes, which ultimately leads to a con-
dition known as diabetic neuropathy (133). LPS is also shown to
aggravate polyclonal B cell activation, which is a similar kind of
condition that occurs in systemic lupus erythematosus (SLE). The
SLE kind of effect from LPS is exerted through increased level of
IgG and IgM serotype and concurrent decrease of IgA specific iso-
topes (134). Receptors for advanced glycation (RAGE) are involved
in negative regulation of LPS induced septic shock that is medi-
ated through reduction in LPS induced inflammatory cytokines
(135). The other glycolipid constituent LTA from bacteria induces
inflammatory responses that are similar to LPS and plays a critical
role in bacteria pathogenesis (130).
TLR9 ligand, CpG-ODNs induces liver injury in d-
Galactosamine sensitized mice that is mediated through excessive
induction of TNF-α leading to mitochondria-mediated apoptosis
of hepatic cells and ultimately culminates in death of the ani-
mal (129). The effect of CpG-ODNs is due to the organization
of constitutive subunits, that is differential for different kind of
CpG-ODNs, and some time it can be fatal to the host. Likewise,
DC-SIGN receptor sensed gp120 from HIV virus inhibits secretion
of inflammatory cytokine IL-6 and phosphorylation and signal
transducer and activator of transcription-3 (STAT-3) that ulti-
mately leads down regulation of host antiviral innate immune
response and that further assist for viral internalization in host
cell into non-endosomal compartments (136). Similarly, glyco-
protein E1 and E2 from HCV modulate host cell entry factors
and escape virus from neutralizing Abs. Hepatitis E virus (HEV)
originated whole virion particles down regulate RIG-I mediated
type-I IFNs production and employ IPS-1 in restricting antiviral
inflammatory response (137). The HN series of influenza virus
H1N1 can escape immune response through antigenic drift that
is enabled by hemagglutinin (HA) head (138). It can be suggested
that pathogens utilizes different strategies for down regulating
host defense mechanism through targeting major innate immune
pathways (129, 136–138). Herewith, these are the few examples
to comprehend the role of SCPs in immune dysregulation and
development of disease; however, proteins PAMPs are prime com-
ponents involved in immune escape mechanism, which is beyond
the scope of this review.
ROLE OF SCPs IN VACCINE BIOLOGY
The term vaccine was coined by Edward Jenner for cowpox, used
for protection from small pox in humans. Formulation of vaccine
can be synthetic or biological, and exerts its effect through activa-
tion of both arms of the immune system, namely, the innate and
adaptive immune system (Figure 3) (139). Therapeutics agents or
antigen alone do not mount appropriate immune responses for
development of immunity against infection; therefore, an addi-
tional immune boosting agent known as adjuvant is required,
which provides enough non-specific immune response to elicit
appropriate immune response against antigenic determinants of
the pathogen and protects the host from infection. Microbial
PAMPs are potential candidates as vaccine adjuvants,which mainly
activate innate immune cells such as macrophages and DCs. The
DCs are pivotal for immunity as they link innate and adaptive
immunity (140). How appropriately the immune system will be
activated by a particular PAMP depends on its structural diversity
and complexity. SCPs such as β-glucan (sensed by Dectin-1 and
NLRP3) are made from the same basic unit of sugar but the bonds
between monomeric subunits vary, which diversifies the structure.
The β-glucan polymer with β 1,6 glycosidic bonds in polymer
chain and β 1,3 glycosidic bonds at branching point is shown to
be associated with immune stimulatory property (141). Formu-
lation of β-glucan adjuvant with candidosis vaccine consists of
α, β mannan-tetanus toxoid complex and enhances protection in
mice against pathogenic C. albicans (142). Furthermore, β-glucan
also functions as a vaccine candidate for immune clearance of
fungal pathogens. Its formulation with immune adjuvant known
as MF59 protects mice from vaginal candidosis infection through
anti-β 1,3 d-glucan Abs (143). In addition to adjuvant and vaccine
for infectious disease, β-glucan is also used for cancer therapeutics
for example yeast derived β-glucan adjuvant potentially enhance
antitumor effect of MUCIN-1 Abs in mice. Adjuvant and vaccine
properties of β-glucan are exerted through induction of innate
cytokines such as IL-6, IL-12, TGF-β, and IL-1β, and Th1 and Th2
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FIGURE 3 | Role of SCPs in vaccine biology. Immunization of host (mice or
human) with vaccine or vaccine adjuvant formulation PTC (PAMPs therapeutic
complex) activates innate immune pathways (TLRs, CLRs, RLRs, NLRs, and
DNA sensors), induce secretion of inflammatory cytokines and type-I IFNs.
These cytokines further activate adaptive immune components through B and
T lymphocytes. Adaptive immune memory cells protects host from infection.
polarization through NLRP3, MyD88, and Syk (141–143). Afore-
mentioned studies suggest that β-glucan can be used as a potential
therapeutic candidate for both infectious and non-infectious dis-
ease. Mannans (α-mannan) from fungus are Dectin-2 ligands,
impart their immune response through CARD9 dependent sig-
naling, and are involved in activation of Th1 cells (73). C. albicans
derived mannans with α 1,6 glycosidic backbone and α 1,2 or α 1,3
glycosidic branching as well β 1,2 linked oligomer in conjugation
with bovine serum albumin protects mice from fungal infection.
This study suggests that similar to β-glucan, α-mannans also pos-
sess vaccine adjuvant property and hence they can be a potential
vaccine candidate for protection from fungal infection (144).
For decades, LPS was known for its adjuvant property; however,
the endotoxic nature renders the use of LPS in immunotherapy
(145). The modified derivative of LPS known as monophosphoryl
lipid A (MPLA) is less toxic and retains its immunostimulatory
activity, and is used as an immunotherapeutic vaccine adjuvant
(146). Co-administration of MPLA along with basic fibroblast
growth factor (bFGF) enhances IgG and IFN-γ level in the serum,
and show antitumor activity in mice. Similarly, formulation of
MPLA with IFN-γ induces secretion of IL-12 from DCs and shows
antitumor activity in mice (147). The antitumor effects of bFGF
growth factor and IFN-γ are exerted through cytokine induced by
DCs for activation of cytotoxic T lymphocytes (CTL). In addition,
these effects are very cell-specific; for example, antitumor effects
of IFN-γ are mediated through CD4+ T cells and selectively elim-
inate human leukocyte antigen (HLA) positive tumor cells (148).
Furthermore, a combination of MPLA and alum is used in humans
as vaccine adjuvant and it has been shown to induce CD8+ T cell
mediated immune responses. Alum induces long-term CD8+ T
cells; however, due to programed death (PD)-1 molecule, differ-
entiation of CD8+ T memory cells to effector cytotoxic T cells
is inhibited. It has been shown that in the combination of MPLA
and alum, MPLA inhibits PD1 activity through IL-6 that ultimately
leads to differentiation of alum primed CD8+ T cells into effec-
tor CTLs, suggesting its application for protection from microbial
pathogens (149). A polymeric form of LPS known as SP-LPS has
immuno-modulatory functions without toxicity. The conjugate of
cancer drug paclitaxel and SP-LPS known as PLC shows promis-
ing antitumor effects through induction of apoptosis. Additionally,
the apoptotic bodies generated during apoptosis further stimulate
antigen presenting cells (APCs) and promote more efficient tumor
clearance (150). Another synthetic derivative of LPS known as
glucopyranosyl lipid (GLA) is shown to function as immune adju-
vant. GLA, along with Mycobacterium tuberculosis (MTB) antigen
ID83 [combination of factor of virulence (Rv2608, Rv3620) and
latency Rv1813)], induces protection against MTB infection in
mice. Furthermore, a GLA and MTB Ag ID3 formulation induces
Th1 cytokines, suggesting that this combination can be used in
humans for protection against MTB infection (151).
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Mincle and TLR2 agonist TDM (also known as MTB cord fac-
tor) is shown to function as immune adjuvant. Co-administration
of TDM with type III pneumococcal polysaccharide (SSS-III) in
mice augments Abs response to SSS-III antigen and further pro-
tects from pneumonia infection (152). A recent genetic study
demonstrated that adjuvant action of TDM activates adaptive
immune responses through MCL; however, Mincle is not essential
(76). The use of TDM is limited due to its toxic nature; a synthetic
analog of TDM known as trehalose-6,6-dibehenate (TDB) does
not show cytotoxic effects in mice. The combination of dimethyl
dioctadecyl ammonium (DDA) and TDB generates a complex
DDA-TDB adjuvant; immunization of mice with DDA-TDB along
with MTB fusion protein (Ag85B-ESAT) shows MTB specific Th1
adaptive immune response through elevation of IFN-γ secret-
ing CD4+T cells and production of isotype Abs IgG2b against
the antigen (153–155), suggesting that DDA-TDB can serve as
potential vaccine adjuvant against MTB. The size of DDA-TDB
vesicle governs antigenic release time and overall it governs cell
mediated adaptive immunity; however, the production of Abs
is independent of vesicle size (156). Furthermore, TDB requires
MyD88 for induction of IL-1β secretion and also activates adaptive
immune response through Th17 cells (156). An in vitro study using
mice bone marrow-derived DCs shows that TDB activates NLRP3
inflammasome in a caspase-1-dependent manner for production
of IL-1β (157).
Lipoarabinomannan (sensed by TLR2 and Mincle) is shown to
elicit protective immune response against Mycobacterium patho-
genesis. Stimulation of cattle peripheral blood mononuclear cells
(PBMCs) with LAM isolated from M. avium along with Fre-
und’s incomplete adjuvant (FIA) induces secretion of IFN-γ. The
immune stimulatory function of LAM is exerted through a MyD88
directed CARD9/NF-κB pathway and NLRP3 inflammasome acti-
vation, suggesting that M. avium LAM could be used as a potential
vaccine candidate against bovine tuberculosis (158). PGN of bac-
teria is not a potent immune adjuvant; however, peptidoglycan
monomer (PGM) induces appropriate immune responses without
any pyrogenic and toxic effects (159). Mice sensitized with PGM
adjuvant and ovalbumin antigen (OVN) formulation enhance
secretion of IFN-γ and IL-4 cytokines and specific anti-OVN Abs.
Similarly, PGM derived from Staphylococcus known as A170PG
protect mice from Staphylococcus infection (160). The adjuvant
effects of PGM are initiated through TLR2 and culminate in acti-
vation of Th1 and Th2 mediated adaptive immune responses. Most
of the studies related to PGM adjuvant are performed using OVN
antigen (159–161). Therefore further studies are required with a
wide range of antigens from pathogens to establish the adjuvant
properties of PGM.
Peptidoglycan teichoic acid (PG-TA) and LTA from Bacillus
subtilis are non-pyrogenic at low concentration and show adju-
vant activity by enhancing the number of granulocyte-monocyte-
colony forming cells in bone marrow in mice. The immune
stimulatory property of these SCPs is possibly mediated through
GM-CSF (162), but the application of PG-TA and LTA as an
immune adjuvant is limited due to poor immunostimulatory func-
tions. The synthetic adjuvant OK-PSA prepared from the cell wall
of non-virulent Streptococcus pyogenes strain OK-432 is struc-
turally similar to LTA and shows potent antitumor effect in mice.
Antitumor effects of OK-PSA are mediated through induction
of IFN-γ, TNF-α, IL-2, IL-12, and IL-18 cytokines from Th1 cells
(163), suggesting its utility as a potent immune adjuvant. Similarly,
GPI anchored proteins (sensed by TLR2/TLR1) are also shown to
possess adjuvant activity (164). Immunization of mice with enzy-
matically cleaved GPI anchored proteins along with membrane
molecules from Schistosoma mansoni potentially protects mice
from worm infection. The adjuvant effect of GPI anchored pro-
teins induces Th1/Th2 responses via IFN-γ and TNF-α produc-
tion (164), suggesting the potential application of GPI anchored
proteins as an adjuvant for protection from parasite infection.
The unmethylated CpG rich DNA from bacteria and virus is
a well-established deoxy pentose sugar containing SCPs. The cel-
lular responses to CpG are mediated through its sensing by the
TLR9 receptor (29). The synthetic analogs of CpG DNA known as
CpG oligodeoxynucleotides (CpG-ODNs) are functionally sim-
ilar to bacterial CpG DNA and show potent immune stimula-
tory property through induction of innate cytokines (IL-6 and
type-I IFNs), improve antigen presentation by DCs, and enhance
humoral and cellular immune responses (165–168). The CpG-
ODNs are structurally different from bacterial DNA; backbone
of bacterial DNA contains phosphodiester while CpG-ODN has
a phosphorothioated (PS) backbone, which protects them from
DNAse in cells. CpG-ODN contains poly G tail at 3′ and 5′ ends,
due to which CpG-ODNs form high molecular weight aggre-
gates, which is responsible for enhanced cellular uptake and potent
immune responses (169, 170). Based on sequence, CpG-ODNs
are classified as type A, B, and C (171, 172); however, another
report shows five types of CpG-ODNs (173). Type A CpG-ODNs
contain phosphodiester backbone, a central CpG dinucleotides
palindrome, and a PS 3′ poly G string, activates natural killer
(NK) cells, and induces high IFN-α production from pDCs but
weakly induces NF-κB dependent inflammatory cytokines. Type
B CpG-ODNs contain full PS backbone with one or more CpG
dinucleotides and are weak inducers of cytokine IFN-α. Type C
CpG-ODNs (with complete PS backbone and CpG palindrome
motif) show combined property of both A and B class CpG-
ODNs and efficiently stimulate B and NK cells and also induce
IFN-α from pDCs. CpG-ODNs from all classes have been used
as immune adjuvants. Immunization of mice with hepatitis B
virus surface antigen (HBsAg) along with type B CpG-ODN
(ODN 1826) enhanced HBsAg-specific IgG2a Abs (174). Similarly,
CpG-ODN 1758 enhances production of tumor surface associated
Id-38C13 antigen-specific IgG2a Abs in mice (175). CpG-ODN
7909 enhances hepatitis B virus (HBV) induced PBMCs prolifer-
ation (176). A study shows that CpG-ODN stimulated secretion
of type-I IFNs from DCs is a dose and time dependent mecha-
nism (177). In addition to these applications, CpG-ODNs have a
wide range of application in therapeutics and discussed in several
reviews (167, 178, 179).
HN series of influenza virus such as H1N1 and H5N1 lyse
PBMCs in IFN-α dependent manner (180). Priming of the host
immune system prior to infection can potentially protect the
host from pathogenesis from influenza. Immunization of mice
with β-propiolactone inactivated (this inactivation does not affect
ssRNA genome of virus) H5N1 and H1N1 virus known as whole
inactivated virus (WIV) protects mice from viral infection. The
immune protection is mediated through TLR7 directed activation
Th1 and Th2 response, as mice lacking TLR7 are susceptible to
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H5N1 infection (181). Furthermore, in vitro stimulation of human
respiratory bronchial epithelial cells with GNR (gold nano rods)
complexed 5′ppp-ssRNA activates RIG-I and MDA5 mediated
antiviral immune memory in these cells, which further protects
from infection with pandemic influenza H1N1 and common
influenza A/Solomon Island/03/06 (182), suggesting the potential
application of viral 5′ppp-ssRNA and WIV as vaccine candidates
for protection from influenza pandemics. Poly(I:C), the synthetic
analog of viral dsRNA (sensed by TLR3, RIG-I, and MDA5), shows
potential antiviral immune response (183). Co-administration of
poly-l-Lysine and carboxymethylcellulose along with poly(I:C)
and with Plasmodium falciparum circumsporozoite protein (CSP)
antigen increase the frequency of activation of CD8+ Th1 cells and
anti-CSP-Abs production (184). Furthermore, immunization of
mice with CpG-ODNs or poly(I:C) and alum adjuvant with HBV
vaccine rAdSS1 [adenoviral vector encoding HBV S (1–223aa) and
pre S (1–47aa) fusion gene] shows immune protection through
CD4+ T cells and CD8+ T cells via IFN-γ and IL-12 production
and inducing cytotoxic effects, suggesting their potential applica-
tion in vaccine biology for protection from HBV (185, 186). Since
it is known that poly(I:C) and CpG-ODNs are potent immune
adjuvant, their use in combination has been shown as poten-
tial immune adjuvant functions. Mice immunized with poly(I:C)
or CpG-ODN 2006 with low dose of salmonid alphavirus (SAV)
antigen preparations show potent induction of type-I IFNs and
further protection from SAV (187). Recently in mice and ferrets,
it was shown that oral administration of an enteric capsule con-
taining adenovirus vector expressing HA from H5N1 virus and a
dsRNA adjuvant enhances antiviral immunity through anti-HA
Abs; however, there is no Abs against adjuvant. Furthermore, this
combination ensures the stability and slow release of viral HA
antigen and dsRNA into the gastrointestinal tract, suggesting the
potential application of enteric capsules as a vaccine candidate
against avian influenza; however, further research work is required
to understand the mechanism for immune activation (188).
Carbohydrate based targeting of CLRs (189) in APCs is an inter-
esting strategy for therapeutic application of synthetic glucans and
glycopolymer. Virus utilizes DC-SIGN for immune escape can
be targeting through synthetic glyconanoparticles such as Man-
LAM (190–192). DC-SIGN mediated internalized glucans further
activate CD4+ and CD8+ cells of adaptive immune system. Fur-
thermore the strategy can be utilized for non-pathogenic disease
like cancer (191) These synthetic glycopolymers can mimic viral
glycoprotein and can be utilized efficiently as antiviral therapeutic
agents (193). In summary, there are potential roads of adjuvant
based vaccine development using formulations of both intact
pathogen and pathogen derived SCPs or their synthetic derivatives.
FUTURE PERSPECTIVES
The complexity of the transcription networks that operate during
SCP sensing and subsequent immune response is a major spotlight
of present research. Although there is enormous progress in the
field of innate immune sensing of pathogenic SCPs, there is still a
lot to understand about the evolving dynamicity of protein–sugar
complex (glycoproteins). Glycoproteins are the most dynamic
PAMPs that pathogens utilize to escape from immune recogni-
tion and therapeutic targets. Synthetic drugs or Abs targeting
protein epitopes can be masked by pathogens through protein
PTM; for example, the HN series of influenza virus has evolved
immune escape mechanism through the glycosylation in HA head,
and during recurrence these viruses show drug resistance. Other
pathogens also utilize such strategies against therapeutic targets;
for example, evolution of drug resistant MTB. Therefore, it is all
about the glycobiome diversity and dynamicity that pathogens
explore as a survival mechanism. Though sugars are the sim-
plest biomolecules, the bonding flexibility with the same sugar,
other sugar, lipids, and proteins generates very complex structures.
Understanding the sugar moieties dynamicity in pathogens is very
crucial for identification of therapeutic targets. It is also necessary
to understand what carbohydrate metabolic pathways are specific
to pathogen survival and are not present in the host. It is also
interesting to implement bio-informatics prediction method to
identify putative PTM sites in structural and non-structural pro-
teins of viruses. Pathogens target particular cells types in the host,
so understanding the epigenetic changes that are modulated by
pathogens in infected cells but are not occurring in uninfected cells
can provide new insights in designing potential therapeutic targets.
Mutation incorporated in viral genomes, genetic polymorphism
of the host, and dynamicity of carbohydrate metabolism in both
the host and pathogens generate a condition that decides latent
or virulent stage of pathogens; for example, a third of the world
population is infected with MTB, but virulence cannot be seen in
all individuals. Therefore, it is very important to consider multiple
factors while designing a therapeutic agent, which mainly includes
comparative glycobiome analysis of the host and the pathogen and
analysis of genetic makeup of the host.
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